XELEVIA ® a drug based on Sitagliptin
THERAPEUTIC GROUP: Oral hypoglycemic agents - DPP-4 inhibitors
IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects
Indications XELEVIA ® - Sitagliptin
XELEVIA ® is indicated in the treatment of type II diabetes mellitus, when non-pharmacological measures or single therapy with metformin, sulfonylureas and agonists of gamma PPARs do not produce the expected results.
The combined therapy between Sitagliptin and the aforementioned active ingredients therefore guarantees better glycemic control than monotherapy.
Mechanism of action XELEVIA ® - Sitagliptin
Sitagliptin, the active substance in XELEVIA ®, belongs to the DPP-4 inhibitors, a new pharmacological family characterized by the hypoglycemic effect.
Taken orally, in fact, it is absorbed at the intestinal level, reaching the maximum plasma concentration within the first 4 hours of intake with an absolute bioavailability of 87%.
Reversibly bound to plasma proteins, about 40% carry out its therapeutic action by inhibiting the enzyme DPP-4 (Dipepetidil Peptidase 4), responsible for the irreversible hydrolysis of hormones known as incretins.
The latter namely the GLP reduce the incidence of side effects observed following monotherapy at high doses.
Broadly speaking, the most described side effects were gastrointestinal reactions such as nausea, vomiting, diarrhea and flatulence, headache and dizziness, and peripheral edema.
Rather clinically more significant and hypersensitive adverse reactions have been observed rarely and have mainly affected cardiac and bone function as well as the haematological profile.
Note
XELEVIA ® can only be sold under strict medical prescription.
